ZA201205385B - Stable growth hormone compounds - Google Patents

Stable growth hormone compounds

Info

Publication number
ZA201205385B
ZA201205385B ZA2012/05385A ZA201205385A ZA201205385B ZA 201205385 B ZA201205385 B ZA 201205385B ZA 2012/05385 A ZA2012/05385 A ZA 2012/05385A ZA 201205385 A ZA201205385 A ZA 201205385A ZA 201205385 B ZA201205385 B ZA 201205385B
Authority
ZA
South Africa
Prior art keywords
growth hormone
stable growth
hormone compounds
compounds
stable
Prior art date
Application number
ZA2012/05385A
Other languages
English (en)
Inventor
Helle Demuth
Leif Norskov-Lauritsen
Peter Thygesen
Christine Bruun Schiodt Schiodt
Jianhe Chen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of ZA201205385B publication Critical patent/ZA201205385B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2012/05385A 2010-01-22 2012-07-18 Stable growth hormone compounds ZA201205385B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29730510P 2010-01-22 2010-01-22
EP10151405 2010-01-22
CN2010001120 2010-07-23
US37860210P 2010-08-31 2010-08-31
PCT/EP2011/050909 WO2011089250A2 (en) 2010-01-22 2011-01-24 Stable growth hormone compounds

Publications (1)

Publication Number Publication Date
ZA201205385B true ZA201205385B (en) 2013-04-24

Family

ID=44166478

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/05385A ZA201205385B (en) 2010-01-22 2012-07-18 Stable growth hormone compounds

Country Status (11)

Country Link
US (1) US9211342B2 (cg-RX-API-DMAC7.html)
EP (1) EP2525833A2 (cg-RX-API-DMAC7.html)
JP (1) JP5980689B2 (cg-RX-API-DMAC7.html)
AU (1) AU2011208620B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012018162A2 (cg-RX-API-DMAC7.html)
CA (1) CA2787895A1 (cg-RX-API-DMAC7.html)
IL (1) IL220648A0 (cg-RX-API-DMAC7.html)
MX (1) MX338357B (cg-RX-API-DMAC7.html)
RU (1) RU2012134974A (cg-RX-API-DMAC7.html)
WO (1) WO2011089250A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205385B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
WO2012010516A1 (en) * 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
JP2016511275A (ja) 2013-03-11 2016-04-14 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
CN106068127B (zh) 2013-12-13 2020-06-19 诺和诺德保健股份有限公司 蛋白质的硫醚缀合方法
US10023581B2 (en) 2015-09-22 2018-07-17 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
KR20180003677A (ko) * 2016-06-30 2018-01-10 주식회사 크레아플래닛 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
DE68929273T2 (de) 1988-08-24 2001-07-05 American Cyanamid Co., Wayne Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
EP0464022B1 (en) 1989-03-20 2000-05-31 The General Hospital Corporation Insulinotropic hormone
US5101018A (en) 1989-06-12 1992-03-31 International Minerals & Chemical Corp. Method for recovering recombinant proteins
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
JP3267293B2 (ja) * 1990-12-03 2002-03-18 ジェネンテク，インコーポレイテッド 改変された結合性を有する変異タンパク質の豊富化法
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
DE69333718T2 (de) 1992-01-14 2005-12-01 Ajinomoto Co., Inc. Gen, das für eine Fisch-Transglutaminase kodiert
DE69334134T2 (de) 1992-07-31 2007-12-20 Genentech, Inc., South San Francisco Wässrige Formulierung enthaltend Menschliches Wachstumshormon
ZA936811B (en) 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1995020662A1 (en) 1994-01-28 1995-08-03 Ajinomoto Co., Inc. Transglutaminase originating in japanese oyster
ATE329014T1 (de) 1994-08-26 2006-06-15 Novozymes As Mikrobielle transglutaminasen, ihre herstellung und ihre verwendung
WO1996010089A1 (en) 1994-09-29 1996-04-04 Ajinomoto Co., Inc. Modification of peptide and protein
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
DE69629719T2 (de) 1995-01-19 2004-07-08 Novozymes A/S Transglutaminasen aus oomyzeten
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
EP0851925B1 (en) 1995-09-21 2005-08-03 Genentech, Inc. Human growth hormone variants
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0929576A1 (en) 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
US6620916B1 (en) 1996-09-26 2003-09-16 Ajinomoto Co., Inc. Modified physiologically active proteins and medicinal compositions containing the same
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
JPH1156378A (ja) * 1997-06-11 1999-03-02 Nippon Chem Res Kk 変異型ヒト成長ホルモンとその用途
PT1775346E (pt) 1997-06-25 2009-08-25 Merck Serono Sa Análogos de hormonas glicoproteicas reticulados com ligações dissulfureto, sua preparação e utilização
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7306931B2 (en) * 2000-05-16 2007-12-11 Bolder Biotechnology, Inc. Method for refolding proteins containing free cysteine residues
JPH1192499A (ja) * 1997-09-22 1999-04-06 Sumitomo Pharmaceut Co Ltd ヒト成長ホルモン変異体
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1060192A2 (en) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
CN100540566C (zh) 1998-12-07 2009-09-16 研究及应用科学协会股份有限公司 胰高血糖素样肽-1的类似物
CA2363712C (en) 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU5805500A (en) 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2003519664A (ja) 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１誘導体の経上皮送達
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
WO2002055532A2 (en) 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
WO2003042245A2 (en) 2001-11-12 2003-05-22 University Of Wales College Of Medicine Growth hormone variations in humans and their uses
KR20070072924A (ko) 2001-11-20 2007-07-06 파마시아 코포레이션 화학적으로 개질된 인간 성장 호르몬 콘쥬게이트
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
FR2836382B1 (fr) 2002-02-28 2004-08-13 Biomerieux Sa Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
JP2005530732A (ja) 2002-04-10 2005-10-13 イーライ・リリー・アンド・カンパニー 胃不全麻痺の治療
DK1499719T3 (da) 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP1594529B1 (en) 2003-02-19 2010-01-20 Ipsen Pharma Analogues of glp-1
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
WO2005014049A2 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
WO2005034988A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Long-acting molecules in sustained release formulations
AU2004298425A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 analogues linked to albumin-like agents
EP1704165B1 (en) 2003-12-18 2010-03-17 Novo Nordisk A/S Glp-1 compounds
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
MXPA06011029A (es) 2004-04-07 2007-01-25 Ares Trading Sa Formulacion liquida de hormona del crecimiento.
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
JP2008507990A (ja) 2004-08-02 2008-03-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｆｖｉｉの抱合体
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097536A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
CN101263225A (zh) 2005-08-18 2008-09-10 诺沃-诺迪斯克保健股份有限公司 改进转谷氨酰胺酶的底物特异性
AU2006286486A1 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
JP2009523815A (ja) * 2006-01-19 2009-06-25 アンブルックス，インコーポレイテッド 免疫原性が調節された非天然アミノ酸ポリペプチド
JP5486809B2 (ja) 2006-02-14 2014-05-07 ノボ ノルディスク ヘルス ケア アーゲー Ｃ末端におけるポリペプチドの結合
MX2008016169A (es) 2006-07-07 2009-01-15 Novo Nordisk Healthcare Ag Nuevos conjugados de proteina y metodos para su preparacion.
CA2672267C (en) 2006-07-27 2016-05-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
CN101506233A (zh) 2006-08-18 2009-08-12 诺沃-诺迪斯克保健股份有限公司 具有提高的特异性的转谷氨酰胺酶变异体
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
WO2008027854A2 (en) 2006-08-31 2008-03-06 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery
EP2129218B1 (en) 2007-02-16 2016-10-19 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
WO2008112836A2 (en) 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2323694A1 (en) 2008-08-06 2011-05-25 Novo Nordisk Health Care AG Conjugated proteins with prolonged in vivo efficacy
EP2324056A1 (en) 2008-09-09 2011-05-25 Novo Nordisk Health Care AG Growth hormone conjugate with increased stability
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
TWI504405B (zh) * 2009-01-22 2015-10-21 Novo Nordisk Healthcare Ag 穩定的生長激素化合物
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2011101261A2 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Purification method

Also Published As

Publication number Publication date
WO2011089250A2 (en) 2011-07-28
JP5980689B2 (ja) 2016-08-31
US9211342B2 (en) 2015-12-15
WO2011089250A3 (en) 2011-10-13
AU2011208620B2 (en) 2015-04-16
MX338357B (es) 2016-04-13
AU2011208620A1 (en) 2012-07-19
RU2012134974A (ru) 2014-02-27
JP2013518037A (ja) 2013-05-20
CA2787895A1 (en) 2011-07-28
MX2012007999A (es) 2012-08-03
IL220648A0 (en) 2012-08-30
US20130040883A1 (en) 2013-02-14
BR112012018162A2 (pt) 2017-10-03
EP2525833A2 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
IL223783A0 (en) Pro-neurogenic compounds
GB201008134D0 (en) Compounds
GB201015949D0 (en) Compounds
ZA201205385B (en) Stable growth hormone compounds
PL2619208T3 (pl) Związki imidazotriazynonu
EP2558391A4 (en) COIL
GB201007347D0 (en) Compounds
ZA201208110B (en) Stabilized agrochemical composition
ZA201206973B (en) Insecticidal compounds
PL2578595T3 (pl) Krystaliczna lewoizowalerylospiramycyna I
EP2649050A4 (en) LINKS
ZA201105419B (en) Stable growth hormone compounds
GB201002563D0 (en) Compounds
GB201008209D0 (en) Compounds
GB201001688D0 (en) Compounds
GB2485393B (en) Reel
GB201002216D0 (en) Compounds
GB201001796D0 (en) Compounds
GB201015537D0 (en) Compounds
GB201008210D0 (en) Compounds
GB201009719D0 (en) Garden problem solution
GB201021494D0 (en) Compounds
GB201013507D0 (en) Compounds
BRPI1006950A2 (pt) compostos de hormônio de crescimento estáveis
GB201018505D0 (en) Grow-bag planter